Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J. Kuter, Janet L. Nichol, Carlos Grande et al.|The Lancet|2008Cited by 862
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITPJames B. Bussel, Janet L. Nichol, David J. Kuter et al.|New England Journal of Medicine|2006Cited by 530
Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodiesLouis M. Aledort, James B. Bussel, Catherine P.M. Hayward et al.|American Journal of Hematology|2004Cited by 194
Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)Terry Gernsheimer, Janet L. Nichol, James N. George et al.|Journal of Thrombosis and Haemostasis|2010Cited by 100
Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.David J. Kuter, Janet L. Nichol, James B. Bussel et al.|Blood|2006Cited by 30